Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider James C. Hamilton Sells 32,729 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now directly owns 272,122 shares in the company, valued at $5,393,458.04. This represents a 10.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR opened at $19.75 on Friday. The firm has a fifty day simple moving average of $21.05 and a two-hundred day simple moving average of $22.53. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. The stock has a market capitalization of $2.46 billion, a P/E ratio of -3.93 and a beta of 0.97. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $17.05 and a 52 week high of $39.83.

Analysts Set New Price Targets

Several research analysts recently weighed in on ARWR shares. Sanford C. Bernstein dropped their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. Finally, Piper Sandler lowered their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $43.33.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Nordea Investment Management AB boosted its holdings in shares of Arrowhead Pharmaceuticals by 6.3% in the 4th quarter. Nordea Investment Management AB now owns 132,188 shares of the biotechnology company’s stock worth $2,463,000 after purchasing an additional 7,776 shares during the period. Franklin Resources Inc. boosted its stake in Arrowhead Pharmaceuticals by 9.4% during the third quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company’s stock worth $373,000 after buying an additional 1,658 shares during the period. World Investment Advisors LLC increased its position in Arrowhead Pharmaceuticals by 3.8% during the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after acquiring an additional 700 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after acquiring an additional 26,171 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $345,000. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.